Skip to main content

PLIANT THERAPEUTICS INC

For the period ended Dec 31, 2023. Filed Feb 27, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 27, 2024

PLRX$0.80-1.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

Page
Special Note Regarding Forward-Looking Statements1
Summary of Risks Associated With Our Business2
PART I
Item 1.Business4
Item 1A.Risk Factors27
Item 1B.Unresolved Staff Comments72
Item 1C.Cybersecurity72
Item 2.Properties73
Item 3.Legal Proceedings73
Item 4.Mine Safety Disclosures73
PART II
Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities74
Item 6.Reserved75
Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations75
Item 7A.Quantitative and Qualitative Disclosures About Market Risk85
Item 8.Financial Statements and Supplementary Data86
Item 9.Changes in and Disagreements With Accountants on Accounting and Financial Disclosure109
Item 9A.Controls and Procedures109
Item 9B.Other Information111
Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections117
PART III
Item 10.Directors, Executive Officers and Corporate Governance113
Item 11.Executive Compensation113
Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters113
Item 13.Certain Relationships and Related Transactions, and Director Independence113
Item 14.Principal Accounting Fees and Services113
PART IV
Item 15.Exhibits and Financial Statement Schedules114

i

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.